SCHEMBL3595381

SCHEMBL3595381

CCc1cc(C(=O)c2ccc(OC(F)(F)F)cc2)c(NC(=O)CSc2ccc(CCC(=O)O)cc2)s1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.56
GFER P55789 1/20 0.51
KDM4E B2RXH2 5/20 0.45
MAPT P10636 5/20 0.45
ALDH1A1 P00352 4/20 0.45
GAA P10253 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 2/20 0.44
HSD17B10 Q99714 2/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
MEN1 O00255 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590071 0.88 NPSR1 (0.53) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3589805 0.87 GFER (0.53) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3593257 0.87 NPSR1 (0.57) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3593123 0.85 NPSR1 (0.52) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3589449 0.83 NPSR1 (0.59) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3581683 0.83 PPARD (0.56) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3587540 0.82 NPSR1 (0.68) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3596025 0.81 NPSR1 (0.61) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3583210 0.81 NPSR1 (0.56) NPSR1GFERKDM4EMAPTALDH1A1
SCHEMBL3585745 0.81 GFER (0.53) NPSR1GFERKDM4EMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2010-03-11 US claimed
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2010-03-11 US disclosed
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2010-03-11 US disclosed
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2010-03-11 US disclosed
EP-1937663-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I Inpharmatica Limited (GB) 2008-07-02 EP disclosed
WO-2007036730-A9 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LTD (GB) 2008-06-19 WO disclosed
WO-2007036730-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I INPHARMATICA LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063065-A1 THIOPHENE DERIVATIVES AS PPAR AGONISTS I PPARG, PPARD, PPARA NPSR1 706/4885GFER 996/4885KDM4E 2668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.